


## ATP synthase inhibitor 1

<b>Cat. No.:</b>	HY-112715
<b>CAS No.:</b>	1023043-30-2
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>18</sub> ClN <sub>3</sub> O <sub>3</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	411.93
<b>Target:</b>	ATP Synthase
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	Powder    -20°C    3 years 4°C        2 years

\* The compound is unstable in solutions, freshly prepared is recommended.



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 5 mg/mL (12.14 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4276 mL	12.1380 mL	24.2760 mL
	5 mM	0.4855 mL	2.4276 mL	4.8552 mL
	10 mM	0.2428 mL	1.2138 mL	2.4276 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F<sub>1</sub>/F<sub>0</sub>-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

F<sub>1</sub>/F<sub>0</sub>-ATP synthase<sup>[1]</sup>

#### In Vitro

ATP synthase inhibitor 1 (Compound 10) is a potent inhibitor of c subunit of the F<sub>1</sub>/F<sub>0</sub>-ATP synthase complex<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Morciano G, et al. Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F<sub>1</sub>/F<sub>0</sub>-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction. J Med Chem. 2018 Aug 23;61(16):7131-7

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA